Home › Leucemia › Illinois › Chicago
Studi clinici su Leucemia a Chicago, IL
16 studi su Leucemia cercano partecipanti presso sedi a Chicago e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
In reclutamentoFase 1/2
- The University of Chicago Medical Center, Chicago
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
In reclutamentoFase 3
- Research Site, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
In reclutamentoFase 1/2
- University of Chicago, Chicago
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
In reclutamentoFase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
In reclutamentoFase 2
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
In reclutamentoFase 1/2
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
In reclutamento
- Northwestern University Feinberg School of Medicine, Chicago
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
In reclutamentoFase 2
- University of Chicago Medical Center, Chicago
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
In reclutamentoStudio osservazionale
- Lurie Children's Hospital-Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
In reclutamentoFase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
In reclutamentoFase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
In reclutamentoFase 1/2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
In reclutamento
- UChicago Medicine Comprehensive Cancer Center, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
In reclutamento
- University of Chicago Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
In reclutamentoFase 1
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Studi su Leucemia in altre città
- Houston, TX28 studi
- Boston, MA25 studi
- New York City, NY19 studi
- Los Angeles, CA16 studi
- Durham, NC13 studi
- Columbus, OH12 studi
- Nashville, TN12 studi
- Baldwin Park, CA12 studi
- Philadelphia, PA12 studi
- Milwaukee, WI11 studi
- Atlanta, GA11 studi
- Seattle, WA11 studi
Altri studi a Chicago
- Cancro del polmone non a piccole cellule61 studi
- Cancro al seno58 studi
- Cancro (tutti i tipi)51 studi
- Cancro alla prostata45 studi
- Cancro metastatico45 studi
- Obesità42 studi
- Cancro ai polmoni41 studi
- Cancro ovarico36 studi
- Ictus34 studi
- Cancro colorettale32 studi
- Insufficienza cardiaca31 studi
- Sovrappeso28 studi
Fonte: ClinicalTrials.gov, dati recuperati il 2 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.